Form 4: Apogee CEO Sells 20,000 Shares Under 10b5-1 Plan

Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of common stock for approximately $1.27 million through a pre-arranged 10b5-1 trading plan.

Summary

• Michael Thomas Henderson, CEO and Director of Apogee Therapeutics, Inc. (APGE), sold a total of 20,000 shares of common stock.
• The sales occurred on February 11, 2026, through three separate transactions.
• The shares were sold at weighted average prices of $62.96, $63.73, and $64.99.
• The total proceeds from these sales amount to approximately $1,270,000.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
• Following these transactions, Mr. Henderson directly beneficially owns 1,172,987 shares of Apogee Therapeutics common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly negative event. While an insider sale can be perceived negatively, the execution under a pre-planned 10b5-1 plan mitigates concerns about opportunistic selling based on undisclosed information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new, non-public information.
• The CEO retains a significant direct beneficial ownership of 1,172,987 shares, demonstrating continued alignment with shareholder interests.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider sales, particularly by a CEO, are often scrutinized by investors. However, the execution under a Rule 10b5-1 plan, adopted well in advance, typically signals a pre-planned liquidity event or portfolio diversification rather than a reaction to adverse, non-public company developments. This is a common practice among executives for managing personal finances.

Comparison to Industry Standards

• StockSavvy.ai observes that insider trading plans (10b5-1 plans) are a standard mechanism for executives across various industries, including biotechnology, to sell shares in a compliant manner.
• For instance, similar pre-scheduled sales are seen at companies like Moderna (MRNA) or Pfizer (PFE) where executives periodically diversify their holdings.
• The volume of shares sold by Mr. Henderson represents a small fraction of his total holdings, which is typical for such diversification efforts, unlike larger, unscheduled sales that might signal a lack of confidence.

Stakeholder Impact

• Shareholders: May view the sale with slight caution, though the 10b5-1 plan reduces the negative signal. The CEO still holds a substantial stake.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

The insider sale by CEO Michael Henderson, while a reduction in his direct holdings, was executed under a pre-arranged 10b5-1 plan. This suggests a planned personal financial move rather than a reaction to new company-specific negative news. Given the significant remaining stake held by the CEO and the pre-planned nature of the transaction, this event alone does not warrant a change in investment thesis. Investors should continue to hold and monitor broader company performance and industry developments.

Keywords

Apogee Therapeutics, APGE, Insider Sale, Form 4, Michael Henderson, CEO, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals